Terence Flynn
Stock Analyst at Goldman Sachs
(4.36)
# 410
Out of 4,479 analysts
148
Total ratings
58.9%
Success rate
13.7%
Average return
Main Sectors:
Top Industries:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Maintains: Buy | $121 → $168 | $109.18 | +53.87% | 5 | May 6, 2024 | |
| AMGN Amgen | Maintains: Equal-Weight | $271 → $310 | $311.01 | -0.32% | 4 | May 3, 2024 | |
| PFE Pfizer | Maintains: Equal-Weight | $28 → $29 | $28.22 | +2.76% | 13 | May 2, 2024 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $168 → $167 | $146.44 | +14.04% | 16 | Apr 17, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $9 → $10 | $20.91 | -52.18% | 3 | Feb 26, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Underweight | $46 → $48 | $53.95 | -11.03% | 6 | Feb 26, 2024 | |
| CCCC C4 Therapeutics | Maintains: Equal-Weight | $1 → $8 | $4.85 | +64.95% | 5 | Feb 26, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $805 → $950 | $914.37 | +3.90% | 15 | Feb 16, 2024 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $38 → $35 | $15.30 | +128.76% | 3 | Nov 13, 2023 | |
| ARVN Arvinas | Maintains: Equal-Weight | $32 → $20 | $25.98 | -23.02% | 7 | Nov 13, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $90 → $85 | $22.47 | +278.28% | 4 | Nov 13, 2023 | |
| RPRX Royalty Pharma | Maintains: Overweight | $54 → $57 | $26.19 | +117.64% | 10 | Nov 9, 2023 | |
| UTHR United Therapeutics | Maintains: Overweight | $318 → $314 | $319.01 | -1.57% | 7 | Nov 2, 2023 | |
| ABBV AbbVie | Maintains: Overweight | $193 → $196 | $170.37 | +15.04% | 9 | Oct 30, 2023 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $115 → $118 | $127.90 | -7.74% | 12 | Oct 27, 2023 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $56 → $50 | $41.30 | +21.07% | 9 | Oct 27, 2023 | |
| RVNC Revance Therapeutics | Maintains: Equal-Weight | $25 → $12 | $2.57 | +366.93% | 7 | Oct 11, 2023 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $27 → $22 | $20.31 | +8.32% | 7 | Oct 11, 2023 | |
| BIIB Biogen | Maintains: Neutral | n/a | $231.77 | - | 3 | Jun 14, 2021 | |
| TBIO Telesis Bio | Initiates: Buy | $342 | $3.86 | +8,760.10% | 1 | Oct 5, 2020 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | n/a | $243.32 | - | 1 | Oct 2, 2017 | |
| FGEN FibroGen | Downgrades: Neutral | n/a | $0.77 | - | 1 | Jul 21, 2017 |
Blueprint Medicines
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $109.18
Upside: +53.87%
Amgen
May 3, 2024
Maintains: Equal-Weight
Price Target: $271 → $310
Current: $311.01
Upside: -0.32%
Pfizer
May 2, 2024
Maintains: Equal-Weight
Price Target: $28 → $29
Current: $28.22
Upside: +2.76%
Johnson & Johnson
Apr 17, 2024
Maintains: Equal-Weight
Price Target: $168 → $167
Current: $146.44
Upside: +14.04%
Nurix Therapeutics
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $20.91
Upside: -52.18%
CRISPR Therapeutics AG
Feb 26, 2024
Maintains: Underweight
Price Target: $46 → $48
Current: $53.95
Upside: -11.03%
C4 Therapeutics
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $4.85
Upside: +64.95%
Eli Lilly
Feb 16, 2024
Maintains: Overweight
Price Target: $805 → $950
Current: $914.37
Upside: +3.90%
Arcus Biosciences
Nov 13, 2023
Maintains: Overweight
Price Target: $38 → $35
Current: $15.30
Upside: +128.76%
Arvinas
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $32 → $20
Current: $25.98
Upside: -23.02%
Intellia Therapeutics
Nov 13, 2023
Maintains: Overweight
Price Target: $90 → $85
Current: $22.47
Upside: +278.28%
Royalty Pharma
Nov 9, 2023
Maintains: Overweight
Price Target: $54 → $57
Current: $26.19
Upside: +117.64%
United Therapeutics
Nov 2, 2023
Maintains: Overweight
Price Target: $318 → $314
Current: $319.01
Upside: -1.57%
AbbVie
Oct 30, 2023
Maintains: Overweight
Price Target: $193 → $196
Current: $170.37
Upside: +15.04%
Merck & Co.
Oct 27, 2023
Maintains: Equal-Weight
Price Target: $115 → $118
Current: $127.90
Upside: -7.74%
Bristol-Myers Squibb Company
Oct 27, 2023
Maintains: Underweight
Price Target: $56 → $50
Current: $41.30
Upside: +21.07%
Revance Therapeutics
Oct 11, 2023
Maintains: Equal-Weight
Price Target: $25 → $12
Current: $2.57
Upside: +366.93%
Organon & Co.
Oct 11, 2023
Maintains: Equal-Weight
Price Target: $27 → $22
Current: $20.31
Upside: +8.32%
Biogen
Jun 14, 2021
Maintains: Neutral
Price Target: n/a
Current: $231.77
Upside: -
Telesis Bio
Oct 5, 2020
Initiates: Buy
Price Target: $342
Current: $3.86
Upside: +8,760.10%
Alnylam Pharmaceuticals
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $243.32
Upside: -
FibroGen
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.77
Upside: -